Home > Drugs A – Z > Insulin Glargine (Injection)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Insulin Glargine (Injection)

Treats diabetes.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Brand names include
Lantus, Lantus SoloStar
Other forms
Subcutaneous route
Drug classes About this

What works? Research summarized

Evidence reviews

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

This review concluded there was some evidence that insulin glargine was more effective than once-daily neutral protamine Hagedorn in reducing nocturnal hypoglycaemia incidence, but there was no evidence of long-term glycaemic control improvement. The review methodology was poorly reported and the available data were limited, but the authors' cautious conclusions reflect the data presented and are likely to be reliable.

Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

The review concluded that glucagon-like peptide-1 receptor agonists, compared to insulin glargine, significantly decreased weight in patients with type 2 diabetes, but increased gastrointestinal adverse events. The influence on mortality or diabetes-associated complications remained unclear. The authors' conclusions reflect the limited short-term evidence, but due to limited data and potential for review bias, they should be interpreted with caution.

A meta-analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mellitus

BACKGROUND: Insulin have been recommended to decrease glycosylated hemoglobin (HbA1c) level in type 2 diabetes mellitus (T2DM) patients whose blood glucose control are unsatisfactory by using oral hypoglycemic drugs.

See all (66)

Summaries for consumers

Insulin detemir versus insulin glargine for type 2 diabetes mellitus

The two long‐acting insulin analogues (artificial insulins), insulin detemir or insulin glargine differ in their mechanism of attaining protracted action, leading to possible differences in glycaemic control and safety outcomes. Several studies have compared either insulin detemir or insulin glargine to NPH (Neutral Protamin Hagedorn) insulin. Research directly comparing both long‐acting insulin analogues is limited.

Type 2 diabetes: Are long-acting insulin analogues better than regular long-acting human insulin?

Long-acting insulin analogues have not been shown to have advantages over human insulin in the treatment of people with type 2 diabetes. More research is needed on the long-term benefits and harms of long-acting insulin analogues.

Type 1 diabetes: Are long-acting insulin analogues better than human insulin?

There is no scientific proof that long-acting insulin analogues are better than long-acting human insulin. There is also a lack of long-term studies looking at the effects of using insulin analogues for many years.

See all (9)

PubMed Health Blog...

read all...